Live Breaking News & Updates on Acituzumab

Stay updated with breaking news from Acituzumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled. | May 10, 2023 ....

United States , Sacituzumab Govitecan , Sacituzumab Govitecan Hziy , Raj Malik , Investor Relations Corporate Communications , European Society For Medical Oncology , Research Triangle Park , Exchange Commission , Therapeutics Inc , American Cancer Society , Target Effect , Trilaciclib Reduces Rates , Multiple Adverse Events Associated , Including Neutropenia , Enrolled Patients Received Prior , Initial Objective Response Rate , Overall Study Population Consistent , Checkpoint Inhibitor Pretreated Population , Tumors Relative , Overall Study Population , Expectation Based , Enhance Anti Tumor Immunity , Currently Expected , First Quarter , Chief Medical Officer , European Society ,

Gilead Sciences, Inc.: Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer

Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Govitecan Significantly Improved Overall Survival in 2L vs. Physician's Choice of Chemotherapy in Metastatic Triple-Negative ....

United States , United Kingdom , Foster City , Great Britain , Jacquie Ross , Sacituzumab Govitecan , Merdad Parsey , Gilead Sciences , European Commission , Gilead Sciences Inc , Exchange Commission , Gilead Public Affairs , European Medicines Agency , Committee For Medicinal Products Human Use , Metastatic Triple Negative Breast , Govitecan Could Offer , New Treatment Option , Aggressive Type , Metastatic Breast Cancer , Medicinal Products , Human Use , Marketing Authorization Application , Chief Medical Officer , Response Evaluation Criteria , Solid Tumors , Triple Negative Breast Cancer ,

GILD: Sacituzumab Govitecan Gets Positive CHMP Opinion For Triple-Negative Breast Cancer Treatment

FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for sacituzumab ....

United States , United Kingdom , Great Britain , Committee For Medicinal Products Human , European Medicines Agency , European Commission , Gilead Sciences Inc , Medicinal Products , Human Use , Marketing Authorization Application ,